BGM GROUP LTD (BGM) Fundamental Analysis & Valuation
NASDAQ:BGM • KYG7307E1237
Current stock price
0.3059 USD
+0.02 (+5.52%)
At close:
0.2961 USD
-0.01 (-3.2%)
After Hours:
This BGM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. BGM Profitability Analysis
1.1 Basic Checks
- In the past year BGM has reported negative net income.
- BGM had a negative operating cash flow in the past year.
- The reported net income has been mixed in the past 5 years: BGM reported negative net income in multiple years.
- BGM had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- BGM has a better Return On Assets (-1.31%) than 76.04% of its industry peers.
- BGM has a Return On Equity of -1.49%. This is in the better half of the industry: BGM outperforms 79.17% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.31% | ||
| ROE | -1.49% | ||
| ROIC | N/A |
ROA(3y)-5.41%
ROA(5y)-0.31%
ROE(3y)-6.51%
ROE(5y)1.12%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With a Gross Margin value of 19.41%, BGM perfoms like the industry average, outperforming 53.13% of the companies in the same industry.
- BGM's Gross Margin has declined in the last couple of years.
- BGM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 19.41% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y18.4%
GM growth 5Y-4.83%
2. BGM Health Analysis
2.1 Basic Checks
- BGM does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, BGM has less shares outstanding
- Compared to 5 years ago, BGM has less shares outstanding
- There is no outstanding debt for BGM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- Based on the Altman-Z score of 1.37, we must say that BGM is in the distress zone and has some risk of bankruptcy.
- The Altman-Z score of BGM (1.37) is comparable to the rest of the industry.
- BGM has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
- BGM has a Debt to Equity ratio (0.01) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.37 |
ROIC/WACCN/A
WACC7.76%
2.3 Liquidity
- BGM has a Current Ratio of 1.82. This is a normal value and indicates that BGM is financially healthy and should not expect problems in meeting its short term obligations.
- BGM has a Current ratio of 1.82. This is in the lower half of the industry: BGM underperforms 66.67% of its industry peers.
- BGM has a Quick Ratio of 1.45. This is a normal value and indicates that BGM is financially healthy and should not expect problems in meeting its short term obligations.
- The Quick ratio of BGM (1.45) is worse than 67.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.82 | ||
| Quick Ratio | 1.45 |
3. BGM Growth Analysis
3.1 Past
- BGM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 74.40%, which is quite impressive.
- Looking at the last year, BGM shows a very negative growth in Revenue. The Revenue has decreased by -10.12% in the last year.
- The Revenue for BGM have been decreasing by -11.45% on average. This is quite bad
EPS 1Y (TTM)74.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-146.9%
Revenue 1Y (TTM)-10.12%
Revenue growth 3Y-23.97%
Revenue growth 5Y-11.45%
Sales Q2Q%13.92%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. BGM Valuation Analysis
4.1 Price/Earnings Ratio
- BGM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. BGM Dividend Analysis
5.1 Amount
- No dividends for BGM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
BGM Fundamentals: All Metrics, Ratios and Statistics
0.3059
+0.02 (+5.52%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)07-24 2025-07-24
Earnings (Next)N/A N/A
Inst Owners0.16%
Inst Owner ChangeN/A
Ins Owners25.02%
Ins Owner ChangeN/A
Market Cap49.70M
Revenue(TTM)26.85M
Net Income(TTM)-2.72M
AnalystsN/A
Price TargetN/A
Short Float %0.12%
Short Ratio0.27
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.85 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.27 | ||
| P/tB | 1.18 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.28
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0.17
BVpS1.12
TBVpS0.26
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.31% | ||
| ROE | -1.49% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 19.41% | ||
| FCFM | N/A |
ROA(3y)-5.41%
ROA(5y)-0.31%
ROE(3y)-6.51%
ROE(5y)1.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y18.4%
GM growth 5Y-4.83%
F-Score3
Asset Turnover0.13
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 151.04% | ||
| Cap/Sales | 6.33% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.82 | ||
| Quick Ratio | 1.45 | ||
| Altman-Z | 1.37 |
F-Score3
WACC7.76%
ROIC/WACCN/A
Cap/Depr(3y)184.23%
Cap/Depr(5y)176.99%
Cap/Sales(3y)4.89%
Cap/Sales(5y)4.34%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)74.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-146.9%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-10.12%
Revenue growth 3Y-23.97%
Revenue growth 5Y-11.45%
Sales Q2Q%13.92%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y39.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-211.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-163.33%
OCF growth 3Y15.85%
OCF growth 5YN/A
BGM GROUP LTD / BGM Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for BGM GROUP LTD?
ChartMill assigns a fundamental rating of 1 / 10 to BGM.
Can you provide the valuation status for BGM GROUP LTD?
ChartMill assigns a valuation rating of 0 / 10 to BGM GROUP LTD (BGM). This can be considered as Overvalued.
What is the profitability of BGM stock?
BGM GROUP LTD (BGM) has a profitability rating of 2 / 10.
Can you provide the financial health for BGM stock?
The financial health rating of BGM GROUP LTD (BGM) is 3 / 10.